Published in Support Care Cancer on January 23, 2013
The effect of technology-based interventions on pain, depression, and quality of life in patients with cancer: a systematic review of randomized controlled trials. J Med Internet Res (2015) 0.81
A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain. Chin J Cancer Res (2014) 0.75
Effects of telemonitoring in cancer patients. Support Care Cancer (2013) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain (1983) 6.46
Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol (2007) 6.35
Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol (2008) 4.70
How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain (2009) 2.55
A randomized controlled trial of a nurse-administered educational intervention for improving cancer pain management in ambulatory settings. Patient Educ Couns (2004) 1.99
Effect of telecare management on pain and depression in patients with cancer: a randomized trial. JAMA (2010) 1.95
Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol (2004) 1.70
Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain (2008) 1.69
Individualized patient education and coaching to improve pain control among cancer outpatients. J Clin Oncol (2001) 1.62
Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage (2002) 1.56
Barriers to effective cancer pain management: a review of the literature. J Pain Symptom Manage (1999) 1.41
The management of cancer pain. CA Cancer J Clin (2011) 1.41
Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.39
Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage (2003) 1.28
Overcoming barriers to cancer pain management: an institutional change model. J Pain Symptom Manage (2007) 1.21
Effect of cancer pain on performance status, mood states, and level of hope among Taiwanese cancer patients. J Pain Symptom Manage (2003) 1.16
Physician attitudes and beliefs about use of morphine for cancer pain. J Pain Symptom Manage (1992) 1.16
Patient barriers to optimal cancer pain control. Psychooncology (2003) 1.14
Depression and quality of life in cancer patients with and without pain: the role of pain beliefs. BMC Cancer (2008) 1.09
The risk of suicide in cancer patients: a review of the literature. Psychooncology (2010) 1.07
Prevalence, severity, and chronicity of pain and general health-related quality of life in patients with localized prostate cancer. Eur J Pain (2007) 1.06
Long-term effectiveness of a patient and family pain education program on overcoming barriers to management of cancer pain. Pain (2006) 1.00
A literature review of suicide in cancer patients. Cancer Nurs (2012) 0.99
A randomized controlled trial of a standardized educational intervention for patients with cancer pain. J Pain Symptom Manage (2010) 0.89
Patient education about cancer pain management: how much time is enough? Pain (2008) 0.81
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol (2007) 3.70
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 2.89
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res (2010) 2.48
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology (2012) 2.40
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut (2012) 2.36
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
GAzer: gene set analyzer. Bioinformatics (2007) 2.04
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol (2012) 1.98
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer (2007) 1.85
Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer. Ann Thorac Surg (2011) 1.80
VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther (2007) 1.75
Robotic total mesorectal excision for rectal cancer using four robotic arms. Surg Endosc (2007) 1.68
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat (2007) 1.68
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol (2012) 1.67
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.63
CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med (2011) 1.59
Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol (2012) 1.56
DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer (2010) 1.55
Collateral pathways in patients with celiac axis stenosis: angiographic-spiral CT correlation. Radiographics (2002) 1.53
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol (2007) 1.53
Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis (2002) 1.53
Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys (2010) 1.52
Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol (2009) 1.50
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer (2011) 1.49
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Onkologie (2011) 1.47
Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol (2008) 1.42
Prediction of short- and long-term survival for advanced cancer patients after ICU admission. Support Care Cancer (2014) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin Cancer Res (2012) 1.39
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol (2012) 1.37
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One (2012) 1.28
Continuous separation of breast cancer cells from blood samples using multi-orifice flow fractionation (MOFF) and dielectrophoresis (DEP). Lab Chip (2011) 1.27
Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med (2011) 1.26
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat (2009) 1.25
Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol (2006) 1.23
Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res (2008) 1.21
Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release (2007) 1.20
Retracted Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei Med J (2012) 1.20
Prognosis of thymic epithelial tumors according to the new World Health Organization histologic classification. Ann Thorac Surg (2004) 1.20
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol (2013) 1.18
Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology (2011) 1.17
The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. J Surg Oncol (2009) 1.17
Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J (2012) 1.16
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther (2012) 1.16
Genome-wide profiles of H2AX and γ-H2AX differentiate endogenous and exogenous DNA damage hotspots in human cells. Nucleic Acids Res (2012) 1.16
Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys (2004) 1.15
A protein interaction network associated with asthma. J Theor Biol (2008) 1.14
Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol (2012) 1.13
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res (2006) 1.12
Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol (2009) 1.11
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer (2012) 1.11
Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol (2009) 1.10